{"id":"https://openalex.org/W7225796173","doi":"https://doi.org/10.3390/pharmaceutics18111462","title":"Real-World Medication Utilization and Potential Pharmacokinetic Drug\u2013Drug Interaction Liabilities in Patients with Heart Failure and Chronic Kidney Disease","display_name":"Real-World Medication Utilization and Potential Pharmacokinetic Drug\u2013Drug Interaction Liabilities in Patients with Heart Failure and Chronic Kidney Disease","publication_year":2026,"publication_date":"2026-11-11","ids":{"openalex":"https://openalex.org/W7225796173","doi":"https://doi.org/10.3390/pharmaceutics18111462"},"language":"en","primary_location":{"id":"doi:10.3390/pharmaceutics18111462","doi":"https://doi.org/10.3390/pharmaceutics18111462","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics18111462","pdf_url":null,"source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3390/pharmaceutics18111462","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088940741","display_name":"Mareena Biju","orcid":"https://orcid.org/0009-0001-7842-567X","observed_orcids":["https://orcid.org/0009-0001-7842-567X"]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP"],"is_corresponding":false,"raw_author_name":"Mareena Biju","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153597761","display_name":"Annie Carlisle","orcid":"https://orcid.org/0009-0001-6218-0997","observed_orcids":["https://orcid.org/0009-0001-6218-0997"]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP"],"is_corresponding":false,"raw_author_name":"Annie Carlisle","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA"],"raw_orcid":"https://orcid.org/0009-0001-6218-0997","affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100450732","display_name":"Ling Zhang","orcid":"https://orcid.org/0000-0002-1463-1458","observed_orcids":["https://orcid.org/0000-0002-1463-1458"]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP"],"is_corresponding":false,"raw_author_name":"Ling Zhang","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061487707","display_name":"Jennifer Schaible","orcid":"https://orcid.org/0009-0004-9449-5792","observed_orcids":["https://orcid.org/0009-0004-9449-5792"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jennifer Schaible","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073001293","display_name":"Beshoy Armanios","orcid":"https://orcid.org/0009-0009-6062-7546","observed_orcids":["https://orcid.org/0009-0009-6062-7546"]},"institutions":[{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP","US"],"is_corresponding":false,"raw_author_name":"Beshoy Armanios","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","School of Pharmacy, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT 06269-3092, USA"],"raw_orcid":"https://orcid.org/0009-0009-6062-7546","affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]},{"raw_affiliation_string":"School of Pharmacy, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT 06269-3092, USA","institution_ids":["https://openalex.org/I140172145"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100717832","display_name":"Xin Chen","orcid":"https://orcid.org/0000-0002-9294-7204","observed_orcids":["https://orcid.org/0000-0002-9294-7204"]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]},{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP","US"],"is_corresponding":false,"raw_author_name":"Xin Chen","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","Center for Translational Medicine, University of Maryland Baltimore, Baltimore, MD 21201, USA"],"raw_orcid":"https://orcid.org/0000-0002-9294-7204","affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]},{"raw_affiliation_string":"Center for Translational Medicine, University of Maryland Baltimore, Baltimore, MD 21201, USA","institution_ids":["https://openalex.org/I126744593"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108122434","display_name":"Ashish Sharma","orcid":"https://orcid.org/0000-0003-2236-3032","observed_orcids":["https://orcid.org/0000-0003-2236-3032"]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP"],"is_corresponding":false,"raw_author_name":"Ashish Sharma","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA"],"raw_orcid":"https://orcid.org/0000-0003-2236-3032","affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5143808992","display_name":"Fenglei Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]},{"id":"https://openalex.org/I4210139229","display_name":"Boehringer Ingelheim (France)","ror":"https://ror.org/03gdpyq31","country_code":"FR","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210139229"]}],"countries":["FR","JP"],"is_corresponding":true,"raw_author_name":"Fenglei Huang","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA","institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5143808992"],"corresponding_institution_ids":["https://openalex.org/I4210122708","https://openalex.org/I4210139229"],"apc_list":{"value":2900,"currency":"CHF","value_usd":3499},"apc_paid":{"value":2900,"currency":"CHF","value_usd":3499},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"18","issue":"11","first_page":"1462","last_page":"1462"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10496","display_name":"Pharmaceutical Practices and Patient Outcomes","score":0.6646000146865845,"subfield":{"id":"https://openalex.org/subfields/2717","display_name":"Geriatrics and Gerontology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10496","display_name":"Pharmaceutical Practices and Patient Outcomes","score":0.6646000146865845,"subfield":{"id":"https://openalex.org/subfields/2717","display_name":"Geriatrics and Gerontology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.31150001287460327,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13970","display_name":"Pharmacy and Medical Practices","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/3611","display_name":"Pharmacy"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7662000060081482},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.6116999983787537},{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.57669997215271},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.5343000292778015},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.5256999731063843},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5054000020027161},{"id":"https://openalex.org/C2781280847","wikidata":"https://www.wikidata.org/wiki/Q409468","display_name":"Metoprolol","level":2,"score":0.5024999976158142},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4812999963760376},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.46470001339912415},{"id":"https://openalex.org/C36434225","wikidata":"https://www.wikidata.org/wiki/Q1895998","display_name":"Polypharmacy","level":2,"score":0.45410001277923584},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4413999915122986},{"id":"https://openalex.org/C2777955127","wikidata":"https://www.wikidata.org/wiki/Q388801","display_name":"Furosemide","level":2,"score":0.4002000093460083},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3668000102043152},{"id":"https://openalex.org/C2777707475","wikidata":"https://www.wikidata.org/wiki/Q422222","display_name":"Digoxin","level":3,"score":0.35749998688697815},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.3481000065803528},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.33899998664855957},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.2890999913215637},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2696000039577484},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.267300009727478}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3390/pharmaceutics18111462","doi":"https://doi.org/10.3390/pharmaceutics18111462","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics18111462","pdf_url":null,"source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3390/pharmaceutics18111462","doi":"https://doi.org/10.3390/pharmaceutics18111462","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics18111462","pdf_url":null,"source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W2078762775","https://openalex.org/W2092128656","https://openalex.org/W2614817248","https://openalex.org/W2791381101","https://openalex.org/W2989346501","https://openalex.org/W3132566478","https://openalex.org/W4319456322","https://openalex.org/W4392777592","https://openalex.org/W4395466179","https://openalex.org/W4399652931","https://openalex.org/W4402766324","https://openalex.org/W4406799570","https://openalex.org/W4409119154","https://openalex.org/W4409691646","https://openalex.org/W4410402400","https://openalex.org/W4412520987","https://openalex.org/W7171492624","https://openalex.org/W7214165452","https://openalex.org/W7214936730"],"related_works":[],"abstract_inverted_index":{"Background/Objectives:":[0],"Patients":[1],"with":[2,43,69,87,104,109,111,187,207],"heart":[3],"failure":[4],"(HF)":[5],"and":[6,47,63,84,90,106,116,124,136,157,164,190,199,219,227,237,246,255],"chronic":[7],"kidney":[8],"disease":[9],"(CKD)":[10],"frequently":[11,176],"receive":[12],"complex":[13],"multidrug":[14],"regimens,":[15],"increasing":[16],"the":[17,33,129,173],"potential":[18,49,183,221],"for":[19,217],"pharmacokinetic":[20,222],"drug\u2013drug":[21],"interactions":[22,68,184],"(DDIs).":[23],"Methods:":[24],"This":[25],"study":[26,240],"used":[27,55,146,177],"U.S.":[28],"Optum\u00ae":[29],"claims":[30],"data":[31],"from":[32],"period":[34],"2019\u20132024":[35],"to":[36,57,242],"characterize":[37],"medication":[38,205],"use":[39],"prevalence":[40,206],"in":[41,142,170,179,197,201,225],"adults":[42],"HF":[44,105,226],"or":[45,151],"CKD":[46,198],"identify":[48],"DDI":[50,210,223,235],"liabilities":[51,153,167,224],"by":[52],"mapping":[53],"commonly":[54,145],"medications":[56,147,178],"established":[58,149,208],"cytochrome":[59],"P450":[60],"(CYP)":[61],"enzyme":[62],"transporter":[64],"pathways.":[65],"Potential":[66],"mechanistic":[67,209],"guideline-directed":[70],"medical":[71],"therapy":[72],"were":[73,127,139,168,185,258],"further":[74],"prioritized":[75],"using":[76],"a":[77,213],"semi-quantitative":[78],"framework":[79,216],"based":[80],"on":[81],"perpetrator":[82],"strength":[83],"substrate":[85,150],"sensitivity,":[86],"Tier":[88,91,188,191],"1":[89,189],"2":[92,192],"representing":[93],"higher-priority":[94],"CYP-mediated":[95],"interaction":[96],"candidates.":[97],"Results:":[98],"The":[99],"analysis":[100],"included":[101],"856,041":[102],"patients":[103,108],"1,893,827":[107],"CKD,":[110,121],"median":[112],"ages":[113],"of":[114,172],"75":[115],"72":[117],"years,":[118],"respectively.":[119],"In":[120],"atorvastatin":[122],"(25.7%)":[123],"metformin":[125],"(19.1%)":[126],"among":[128],"most":[130,175],"prevalent":[131,141],"medications,":[132],"while":[133],"metoprolol":[134],"(33.2%)":[135],"furosemide":[137],"(31.9%)":[138],"highly":[140],"HF.":[143,202],"Many":[144],"had":[148],"inhibitor":[152],"involving":[154,195],"CYP3A,":[155],"CYP2D6,":[156],"transporters":[158],"including":[159],"P-gp,":[160],"OATP1B,":[161],"MATE,":[162],"OCT2,":[163],"BCRP.":[165],"CYP3A":[166,196],"identified":[169],"13":[171],"25":[174],"each":[180],"population.":[181],"Higher-priority":[182],"pathway-specific,":[186],"candidates":[193],"primarily":[194],"CYP2D6":[200],"Integrating":[203],"real-world":[204],"information":[211],"provides":[212],"practical,":[214],"hypothesis-generating":[215],"identifying":[218],"prioritizing":[220],"CKD.":[228],"Conclusions:":[229],"These":[230],"findings":[231],"may":[232],"inform":[233],"subsequent":[234],"evaluations":[236],"clinical":[238,253],"pharmacology":[239],"planning":[241],"support":[243],"drug":[244],"development":[245],"future":[247],"risk-mitigation":[248],"strategies,":[249],"although":[250],"actual":[251],"co-exposure,":[252],"DDIs,":[254],"associated":[256],"outcomes":[257],"not":[259],"assessed.":[260]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-11-12T00:00:00"}